Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy

We herein report a case of pneumocystis pneumonia (PCP) in a 77-year-old woman with ovarian cancer who was receiving olaparib therapy. After the patient's second relapse of ovarian cancer, she was administered olaparib as maintenance therapy following successful completion of docetaxel and carboplatin therapy. On receiving olaparib, she showed symptoms of a fever and malaise. Based on laboratory and imaging findings, she was diagnosed with PCP. After treatment with corticosteroids and trimethoprim/sulfamethoxazole followed by atovaquone, the patient's general condition improved. The lymphocytopenia observed after olaparib administration may have been associated with the development of PCP.

[1]  I. Ray-Coquard,et al.  First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion , 2020, ESMO Open.

[2]  S. Tasaka.  Recent Advances in the Diagnosis and Management of Pneumocystis Pneumonia , 2020, Tuberculosis and respiratory diseases.

[3]  Weixiong Yang,et al.  A review of current progress in triple-negative breast cancer therapy , 2020, Open medicine.

[4]  F. Marmé,et al.  Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. , 2019, The New England journal of medicine.

[5]  M. Hoenigl,et al.  Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia , 2018, Respiration.

[6]  Val Gebski,et al.  Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[7]  Ke Wang,et al.  Diagnosis of pneumocystis pneumonia using serum (1-3)-β-D-Glucan: a bivariate meta-analysis and systematic review. , 2015, Journal of thoracic disease.

[8]  E. Winer,et al.  Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors , 2015, Breast Cancer Research and Treatment.

[9]  O. Decaux,et al.  Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. , 2014, The American journal of medicine.

[10]  T. Betsuyaku,et al.  Serum (1 → 3) β-D-glucan assay for discrimination between Pneumocystis jirovecii pneumonia and colonization. , 2014, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[11]  D. Matei,et al.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial , 2014 .

[12]  D. Matei,et al.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[13]  S. Ichiyama,et al.  Quantitative real-time PCR and the (1→3)-β-D-glucan assay for differentiation between Pneumocystis jirovecii pneumonia and colonization. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[14]  A. Morris,et al.  Colonization by Pneumocystis jirovecii and Its Role in Disease , 2012, Clinical Microbiology Reviews.

[15]  S. Sungkanuparph,et al.  Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. , 2011, Seminars in arthritis and rheumatism.

[16]  仲村 秀太.  Clinical utility of serum β-D-glucan and KL-6 levels in Pneumocystis jirovecii pneumonia , 2011 .

[17]  E. Calderón.  Pneumocystis infection: seeing beyond the tip of the iceberg. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  S. Chevret,et al.  Polymerase chain reaction for diagnosing pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. , 2009, Chest.

[19]  E. Winer,et al.  Lymphopenia associated with adjuvant anthracycline/ taxane regimens. , 2008, Clinical breast cancer.

[20]  T. Johkoh,et al.  Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study. , 2008, Internal medicine.

[21]  Kenichi Tanaka,et al.  Pneumocystis carinii pneumonia in a patient with stage IV ovarian cancer. , 2002, Gynecologic Oncology.

[22]  K. Sepkowitz,et al.  Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. , 1992, JAMA.